手术在IDH突变型4级星形细胞瘤中的作用:切除范围、患者特征与结局的交互效应——RANO切除组报告
该国际研究纳入266例IDH突变型4级星形细胞瘤患者,分析术后残余肿瘤对生存的影响。结果显示残余对比增强肿瘤越少生存越长,超最大范围切除者结局最佳;CDKN2A/B缺失与更差生存相关,且不受切除程度影响。提示在安全前提下尽可能多切除增强肿瘤可能改善结局,并为未来临床试验的风险分层提供依据。
要点
- 术后残余对比增强肿瘤越少,IDH突变型4级星形细胞瘤患者生存越长。
- 超最大范围切除(超出可见增强部分)者结局最有利。
- CDKN2A/B缺失与更差生存相关,且不受切除程度影响。
核心结论
- 在安全前提下尽可能多切除对比增强肿瘤可能改善IDH突变型4级星形细胞瘤患者结局,并可用于未来临床试验风险分层。
研究设计与样本
- 国际研究,纳入266例IDH突变型4级星形细胞瘤患者,分析切除范围、患者特征与结局的交互效应。
主要发现
- 术后残余对比增强肿瘤越少,患者生存越长。
- 接受超最大范围切除(切除超出可见增强部分)的患者结局最有利。
- CDKN2A/B基因缺失与更差生存相关,且与切除范围无关。
临床怎么用
- 在安全可行前提下,应尽可能多地切除对比增强肿瘤以改善生存。
- CDKN2A/B缺失状态可用于风险分层,不受切除程度影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgery is the first step in treating patients with the rare brain tumor IDH-mutant grade 4 astrocytoma. In an international study of 266 patients, we examined how the amount of tumor remaining after surgery affects survival. Patients with less remaining contrast-enhancing tumor lived longer. Those who underwent ‘supramaximal’ surgery (tumor removal beyond the visible enhancing portion) had the most favorable outcomes. Loss of the CDKN2A/B gene was linked to worse survival regardless of the extent of surgery. These findings suggest that removing as much enhancing tumor as safely possible may improve outcomes and guide risk stratification in future clinical trials.
引用
- Karschnia P, Youssef G, Young JS, et al. The role for surgery in IDH-mutant grade 4 Astrocytomas: interactive effects of resection, patient characteristics, and outcome - report of the RANO resect group. Neuro Oncol. 2026. PMID: 42671346. doi:10.1093/neuonc/noag199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。